Precipio Launches ICE COLD-PCR(TM) Research Access Program for Cancer Centers

COMPLIMENTARY PRECIPIO ICE COLD PCR™  KITS NOW AVAILABLE TO ADVANCE BODY OF RESEARCH AND ACCELERATE MARKET EXPANSION NEW HAVEN, Conn., April 11, 2018 (GLOBE NEWSWIRE) — Specialty diagnostics company Precipio, Inc. (NASDAQ:PRPO), announced today the launch of its program to provide complimentary ICE COLD-PCR (ICP) kits to cancer researchers studying the field of liquid biopsy. The program... Read more

HudsonAlpha Using PacBio Sequencing for Childhood Developmental Disabilities Research

MENLO PARK, Calif., April 11, 2018 (GLOBE NEWSWIRE) — Pacific Biosciences of California, Inc. (Nasdaq:PACB), the leader in long-read, high-resolution sequencing, today announced that the HudsonAlpha Institute for Biotechnology is using the organization’s newest Sequel® Sequencing System to support the goal of dramatically increasing the diagnostic success rate in challenging pediatric clinical cases. Led by... Read more

SCIEX launches the Citrine™ Triple Quad™ MS/MS Systems in Europe, bringing maximal speed and sensitivity to clinical diagnostics testing

The SCIEX Citrine™ MS/MS medical device provides clinical labs with one solution to tackle today’s difficult assays, and the versatility to address tomorrow’s precision medicine and wellness testing April 10, 2018 Darmstadt, Germany — SCIEX Diagnostics, the in vitro diagnostics division of SCIEX, a global leader in mass spectrometry in the life sciences industry, is launching the Citrine™... Read more

Illumina and Loxo Oncology to Partner on Developing Next-Generation Sequencing-Based Pan-Cancer Companion Diagnostics

SAN DIEGO & STAMFORD, Conn.–(BUSINESS WIRE)–Illumina, Inc. (Nasdaq: ILMN) and Loxo Oncology (Nasdaq: LOXO) today announced a global strategic partnership to develop and commercialize a multi-gene panel for broad tumor profiling, resulting in a distributable, next-generation sequencing (NGS) based companion diagnostic (CDx) with a pan-cancer indication. The co-development partnership will seek approval for a version... Read more

New SPE Solution Streamlines Urine Drug Testing Workflow

Torrance, Calif. (April 10, 2018) – Phenomenex Inc., a global leader in the research and manufacture of advanced technologies for the separation sciences, introduces Strata®-X-Drug B Plus – a solid phase extraction (SPE) sample preparation product for urine drug testing in clinical and forensic toxicology labs. An expansion of Phenomenex’s drug testing product line, the new Drug B Plus... Read more

New Compounds Now Available for Antimicrobial Susceptibility Testing: Delafloxacin and Meropenem/Vaborbactam

New Compounds Now Available for Antimicrobial Susceptibility Testing: Delafloxacin and Meropenem/Vaborbactam FDA-cleared microbroth dilution plates provide true minimum inhibitory concentration (MIC) results, facilitating more targeted patient therapy OAKWOOD VILLAGE, Ohio, April 5, 2018 /PRNewswire/ — The antimicrobial delafloxacin, and the combination of meropenem and vaborbactam are now available on FDA-cleared microbroth dilution susceptibility plates, expanding antimicrobial... Read more

Parent Project Muscular Dystrophy Selects PerkinElmer to Support Decode Duchenne Program

April 5, 2018 at 8:15 AM EDT PDF Version WALTHAM, Massachusetts – April 5, 2018 – PerkinElmer, Inc., a global leader committed to innovating for a healthier world, today announced that Parent Project Muscular Dystrophy (PPMD) has selected the Company to provide genetic testing for its Decode Duchenne program.    Duchenne muscular dystrophy (Duchenne) is the most common genetic disorder diagnosed in... Read more

Exactis Innovation Selects Ion GeneStudio S5 Systems and Oncomine Assays to Drive Canadian Clinical Trial Studies

Exactis Innovation Selects Ion GeneStudio S5 Systems and Oncomine Assays to Drive Canadian Clinical Trial Studies Laboratory network standardizes on common NGS platform to efficiently profile patient samples across multiple cancer centers CARLSBAD, Calif., March 28, 2018 /PRNewswire/ — At risk cancer patients across Canada may now be able to have their tumors molecularly profiled... Read more

Pacific Biosciences Announces Ten-Unit Sequel System Order for Annoroad

MENLO PARK, Calif., March 27, 2018 (GLOBE NEWSWIRE) — Pacific Biosciences of California, Inc. (Nasdaq:PACB), the leader in long-read, high-resolution sequencing, today announced a purchase order for 10 PacBio® Sequel® Systems that are expected to be installed at Annoroad’s designated facility within the next several months, enhancing Annoroad’s large-scale genomic service capabilities across various fields... Read more

Agena and Simceredx Announce Strategic Partnership to Develop and Commercialize Companion Diagnostics in China

26 March 2018 San Diego, Calif., and Nanjing, JiangSu, March 26, 2018 – Agena Bioscience (Agena) and Simcere Diagnostics (Simceredx), the subsidiary of SIMCERE Pharmaceutical Group, announced today the signing of a strategic partnership agreement focusing on expanding the use of Agena’s MassARRAY® System for companion diagnostics and pharmacogenetic testing in China. As a leading pharmaceutical... Read more